Anavex says FDA grants meeting request on adding pediatric patients to Phase 3 Rett syndrome trial of blarcamesine

Reuters2026/09/09 21:18

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Anavex disclosed FDA granted a meeting to discuss adding pediatric patients to its Phase 3 Rett syndrome trial of ANAVEX 2-73.
No clinical results were presented, with the update focused on potential trial expansion rather than study outcomes.
The move could broaden the addressable patient population, supporting the strategic push behind the Rett syndrome program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anavex Life Sciences Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001731122-26-001211), on September 09, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Anavex says FDA grants meeting request on adding pediatric patients to Phase 3 Rett syndrome trial of blarcamesine

You may also like

Crypto prices